10-Q: FibroBiologics Q3 Loss Widens Amid R&D Spend, Going Concern Doubt

FibroBiologics reported a significantly wider net loss in Q3 2025, driven by increased R&D expenses, while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

Summary

• Net loss for the three months ended September 30, 2025, significantly widened to $5.8 million, compared to $0.5 million for the same period in 2024.
• Year-to-date net loss for the nine months ended September 30, 2025, was $15.4 million, up from $8.1 million in the prior year.
• Research and development expenses increased by $1.6 million for the quarter and $3.5 million year-to-date, primarily due to increased CRO costs for clinical trial preparation, contract research, lab facilities, personnel, and research materials.
• Cash and cash equivalents decreased to $4.9 million as of September 30, 2025, from $14.0 million at December 31, 2024.
• The company has an accumulated deficit of $50.9 million as of September 30, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern for the next year, citing ongoing operating losses and dependence on additional capital.
• Timelines for the Phase 1/2 clinical trial of CYWC628 in Australia for diabetic foot ulcers have been extended to Q1 2026 for initiation and Q3 2026 for completion, due to manufacturing process issues.
• The company faces Nasdaq delisting threats for failing to meet the $1.00 minimum bid price and the $35.0 million minimum market value of listed securities requirements.
• A material weakness in internal control over financial reporting due to a lack of segregation of duties was identified.

Sentiment

Score: 3

Explanation: The company reported significantly wider losses, a substantial decrease in cash, and explicitly stated 'substantial doubt about our ability to continue as a going concern.' It also faces multiple Nasdaq delisting threats and manufacturing delays for a key clinical trial. While there is ongoing R&D and some positive preclinical/Phase 1 results, the severe financial and operational challenges outweigh these, indicating a highly negative sentiment.

Positives

• Formation of a wholly-owned subsidiary, FibroBiologics Australia Pty Ltd, to sponsor the Phase 1/2 clinical trial for CYWC628 in Australia.
• Completion and certification of the master cell bank and working cell bank for CYWC628.
• Positive preclinical results for CYWC628 showed statistically significant acceleration in wound closure and improved quality of healed wounds compared to a marketed product and control.
• Successful completion of a Phase 1 study for CYMS101 in Mexico, demonstrating no adverse events related to treatment and assessing clinical activity.
• Positive animal study results for CybroCell in rabbit models supported IND clearance from the FDA in 2018.
• The company has access to an additional $10.0 million in potential funding through the Standby Equity Purchase Agreement (SEPA) until December 20, 2026.
• Implemented measures to reduce operating expenses, including delaying certain R&D projects, limiting finance, legal, and administrative costs, and pursuing options to limit spend on office space.

Negatives

• Net loss significantly widened to $5.8 million for the three months ended September 30, 2025, from $0.5 million in the prior year period.
• Year-to-date net loss increased to $15.4 million for the nine months ended September 30, 2025, from $8.1 million in the prior year period.
• Cash and cash equivalents decreased by $9.1 million to $4.9 million as of September 30, 2025, from $14.0 million at December 31, 2024.
• Accumulated deficit grew to $50.9 million as of September 30, 2025.
• The company does not generate revenue and expects to continue incurring significant losses for the foreseeable future.
• A net loss of approximately $0.9 million was recognized on the conversion of convertible debt into common stock during the nine months ended September 30, 2025.
• The company identified a material weakness in internal control over financial reporting due to a lack of segregation of duties.

Risks

• Substantial doubt about the ability to continue as a going concern for one year from the issuance of the financial statements, dependent on raising additional capital.
• Inability to obtain additional financing or enter into revenue-generating collaborations on acceptable terms when needed.
• Potential for further delays, reductions, or discontinuation of research and development programs if unable to obtain adequate financing.
• Complexity and inherent risks in manufacturing cell therapy products, including difficulties in production, sourcing, scaling up, validating processes, quality control, and potential contamination.
• Extended timelines for the CYWC628 Phase 1/2 clinical trial in Australia due to process issues with manufacturing training runs and the need for more aseptic process simulation runs to confirm sterility.
• Variability in donor cell material for product candidates, potentially leading to production failures, lower quality batches, or delays.
• Logistical and shipment delays or shortages of clinical/commercial-grade supplies and components could prevent or delay product delivery.
• Failure to maintain a complex chain of identity and custody for donor material could result in patient death, product loss, or regulatory action.
• Reliance on third-party contract manufacturers (CDMOs) for compliance with cGMPs, with no direct control over their processes, quality control, or personnel.
• Potential for sanctions (clinical holds, fines, injunctions, etc.) if the company or third-party manufacturers fail to comply with regulations.
• Difficulties in scaling up to commercial quantities and formulation of product candidates, with potentially prohibitive manufacturing costs.
• Changes in manufacturing methods or formulation may result in additional costs, delays, or require further testing and regulatory approval.
• Failure to maintain compliance with Nasdaq continued listing requirements (minimum bid price of $1.00 and minimum market value of listed securities of $35.0 million) could lead to delisting.
• Delisting from Nasdaq could negatively impact stock liquidity, make it harder to raise capital, and incur additional costs under state blue sky laws.
• The company is subject to all risks typically related to the development of new product candidates, including unforeseen expenses, difficulties, complications, and delays.

Future Outlook

The company expects to continue incurring significant operating losses as it advances product candidates through clinical development and seeks regulatory approvals. It anticipates substantial increases in R&D expenses, manufacturing costs, and public company operating expenses. The ability to generate revenue and achieve profitability is heavily dependent on the successful development, approval, and commercialization of product candidates. The company will require substantial additional funding, likely through equity sales, debt financings, or collaborations, and may need to delay or reduce development efforts if capital is not secured. Specific timelines include initiating the CYWC628 Phase 1/2 trial in Australia in Q1 2026 (completing Q3 2026) and filing an IND for CYMS101 Phase 1/2 trial in the U.S. in Q4 2025.

Management Comments

• "We have incurred operating losses since Inception and expect such losses to continue in the future as it builds infrastructure, develops intellectual property, and conducts research and development activities."
• "A transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure."
• "Unless and until such time that revenue and net income are generated, the Company will need to continue to raise additional capital."
• "These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the unaudited condensed consolidated financial statements."
• "We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we advance the development of our product candidates through clinical development, and, if approved by the FDA, commercialization."
• "We expect to rely on third parties for our cell therapy manufacturing process for the foreseeable future."
• "We plan to accelerate such programs [human longevity, certain cancers, and artificial pancreatic organoid research] as funding allows."
• "We plan to file an IND application for a Phase 1/2 clinical trial relating to MS in the United States in the fourth quarter of 2025."
• "We expect to seek a strategic partner to collaborate with us on the development of CYMS101 either before initiating the Phase 1/2 study, or after its completion, if successful, and prior to commencing a potential Phase 3 clinical trial."
• "Timelines for our planned twelve-week Phase 1/2 clinical trial utilizing CYWC628 for treatment of diabetic foot ulcers in Australia have been extended as we work to resolve process issues with the manufacturing training runs and increase the number of aseptic process simulation runs needed to confirm sterility of the manufacturing process before we begin the manufacturing of CYWC628 for the clinical trial."
• "We believe we will be able to obtain additional capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on acceptable terms."
• "During the nine months ended September 30, 2025, we have implemented measures to reduce operating expenses including delaying certain research and development project spend while prioritizing near term pipeline projects, limiting finance, legal and administrative costs, and pursuing options to limit spend on office space."

Industry Context

FibroBiologics operates in the highly capital-intensive and risky clinical-stage cell therapy biotechnology sector. The company's focus on fibroblast-based therapies for chronic diseases like multiple sclerosis, degenerative disc disease, psoriasis, and wound healing places it in a competitive landscape with other biotech firms developing advanced therapies. The reliance on third-party contract development and manufacturing organizations (CDMOs) is common in this industry, but also introduces manufacturing and supply chain risks, as highlighted by the delays in the CYWC628 trial. The need for substantial ongoing funding through equity or debt is typical for early-stage biotech companies that do not yet generate revenue, and the challenges with Nasdaq listing requirements reflect the difficulties smaller, pre-revenue companies face in maintaining public market visibility and access to capital.

Comparison to Industry Standards

• The company's significant operating losses and accumulated deficit are typical for early-stage biotechnology companies engaged in extensive research and development, which often require substantial capital investment over many years before potential product commercialization.
• The reliance on third-party contract manufacturing organizations (CDMOs) for cell therapy production is a common industry practice, especially for smaller biotech firms that lack in-house cGMP facilities. However, the reported 'process issues with the manufacturing training runs' for CYWC628 highlight a common challenge in scaling up complex biologic manufacturing, which can lead to delays, similar to issues faced by other cell and gene therapy developers.
• The company's pursuit of multiple product candidates (CYWC628, CYMS101, CybroCell, CYPS317) across various indications is a standard strategy in biotech to diversify risk, given the high failure rate of drug development.
• The need to raise additional capital through equity or debt is standard for pre-revenue biotech companies. The Standby Equity Purchase Agreement (SEPA) is a common financing mechanism for smaller public companies to access capital on an 'at-the-market' basis, though it often comes with dilutive effects.
• The Nasdaq listing challenges (minimum bid price and market value) are frequently encountered by smaller, pre-revenue biotech companies whose stock prices can be volatile and market capitalizations fluctuate significantly based on clinical progress and funding news. This is not unique to FibroBiologics but reflects broader market sentiment towards high-risk, high-reward ventures.

Corporate Governance

Related Party Transactions

• Paid $62,400 to a member of the Board of Directors for strategic advisory services, including support for finance and capital raising activities, during the nine months ended September 30, 2025. The statement of work for this agreement has expired.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing convertible debt conversions and future equity raises. Potential for further share price decline due to widening losses, going concern doubt, and Nasdaq delisting threats.
• Employees' continued employment and growth are dependent on successful capital raises and clinical trial progress. Potential for staffing increases in financial reporting if internal control weaknesses are remediated.
• Future customers may experience delays in the availability of potential fibroblast-based therapies due to clinical trial setbacks.
• Creditors face increased risk due to the company's going concern doubt and reliance on future capital raises to meet obligations.
• Suppliers and CDMOs may see increased business if clinical trials progress, but also face risks of payment delays if funding is insufficient.

Next Steps

• Initiate the twelve-week Phase 1/2 clinical trial for CYWC628 for diabetic foot ulcers in Australia in Q1 2026.
• Complete the CYWC628 clinical trial in Australia in Q3 2026.
• File an IND application for a Phase 1/2 clinical trial relating to MS (CYMS101) in the United States in Q4 2025.
• Seek a strategic partner for the development of CYMS101 before or after the Phase 1/2 study.
• Continue IND-enabling animal model studies for CYPS317 (psoriasis), expecting completion in Q4 2025.
• Plan to file an IND for CYPS317 following completion of studies if results support continued development.
• Conduct animal trials for CybroCell to confirm therapeutic effects of CYWC628 spheroids are similar to single-cell fibroblasts.
• If animal trials for CybroCell are positive, work to amend the IND clearance with the FDA to replace single-cell fibroblasts with CYWC628 spheroids.
• Accelerate human longevity, certain cancers, and artificial pancreatic organoid research programs as funding allows.
• Implement measures to reduce operating expenses, including delaying certain R&D projects, limiting finance, legal, and administrative costs, and pursuing options to limit office space.
• Address the material weakness in internal control over financial reporting by adding staff and evaluating segregation of duties as funding allows.
• Actively monitor performance and consider options to regain compliance with Nasdaq listing standards (minimum bid price by December 29, 2025, and minimum market value by February 2, 2026).
• Raise additional capital through equity financings, debt financings, collaborations, or other licensing arrangements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by significantly widening losses, rapidly depleting cash reserves, and an explicit "substantial doubt about our ability to continue as a going concern." This is compounded by multiple Nasdaq delisting threats and critical manufacturing delays impacting a key clinical trial. While there are ongoing R&D efforts, the immediate and severe financial and operational challenges present an extremely high risk profile. The continuous conversion of convertible debt at decreasing prices indicates significant dilution and downward pressure on the stock. Without a clear path to sustained funding and resolution of listing issues, the investment risk is exceptionally high.

Keywords

FibroBiologics, cell therapy, biotechnology, SEC filing, 10-Q, financial results, net loss, R&D expenses, going concern, Nasdaq delisting, clinical trials, CYWC628, CYMS101, CybroCell, CYPS317, diabetic foot ulcers, multiple sclerosis, degenerative disc disease, psoriasis, fibroblast cells, biopharmaceutical development, capital raise, convertible debt, manufacturing issues, internal controls